VERTEX PHARMACEUTICALS INC
AI Health Factor Performance Trends
Latest Insights
26 December, 2024
Vertex Pharmaceuticals Faces Stock Volatility Following Mixed Clinical Trial Results Despite Strong Cystic Fibrosis Portfolio
25 December, 2024
Vertex Pharmaceuticals Faces Stock Volatility Following Mixed Clinical Trial Results Despite Strong Cystic Fibrosis Portfolio
24 December, 2024
Vertex Pharmaceuticals Faces Stock Decline Amid Mixed Phase 2 Study Results for Pain Drug Suzetrigine, But Analysts Remain Optimistic About Future Growth and FDA Approvals
23 December, 2024
Vertex Pharmaceuticals Stock Drops 14% Despite Meeting Primary Endpoint in Phase 2 Study for Non-Opioid Pain Drug Suzetrigine
22 December, 2024
Vertex Pharmaceuticals' Stock Plummets Over 10% Following Mixed Results for Non-Opioid Pain Drug Suzetrigine
Most Read
Join Foliko Premium!
Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.
Go Premium - 7 Day Free Trial